Growth Hormone Axis Research High Evidence

Tesamorelin

Stabilized GHRH analogue (trans-3-hexenoic acid modification). FDA-approved for HIV-associated lipodystrophy. Extensively studied in multiple human RCTs.

ghrhFDAlipodystrophyvisceral fatcognitivegrowth hormone

Ask AI About This Compare Compounds

Half-life

26 minutes

SKUs

Evidence

High Evidence

📖 What Is This?

Tesamorelin is a synthetic analog of GHRH (growth hormone releasing hormone) that is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy — a condition where excess visceral fat accumulates in the abdomen as a side effect of antiretroviral therapy. It is one of the few GHRH analogs to have received FDA approval, making it a well-characterized compound with an established clinical evidence base.

🔬 What Are Researchers Studying It For?

HIV Lipodystrophy

Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-infected adults on antiretroviral therapy. Phase 3 trials showed significant reductions in visceral adipose tissue measured by CT scan, with improvements in waist circumference and lipid profiles.

Non-Alcoholic Fatty Liver Disease

Research has examined tesamorelin for liver fat reduction in non-HIV populations, based on its effects on visceral fat and GH/IGF-1 axis activity. A randomized trial showed significant reductions in liver fat content, expanding interest beyond the HIV indication.

Cognitive Aging Research

A randomized trial in older adults examined whether tesamorelin could improve cognitive function by restoring IGF-1 levels that decline with aging-associated GH decline. Results showed improvements in cognitive performance versus placebo, particularly in executive function.

📊 What Does The Research Suggest?

FDA-approved for HIV-associated lipodystrophy with well-established trial evidence.
Reduces visceral fat measured by CT scan in both HIV and non-HIV populations.
Randomized trial shows liver fat reduction in non-alcoholic fatty liver disease.
Cognitive improvement signals in aged adults in a randomized trial.
Works through stimulating natural GH production rather than delivering exogenous HGH.

⚠️ What Should You Know Before Going Deeper?

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy — not for general fat loss, anti-aging, or other indications. Off-label use should be considered investigational. Visceral fat may return after stopping treatment. It requires daily injections. Fluid retention and joint discomfort are possible side effects related to GH elevation.

⚙️ How It Works In The Body

Tesamorelin is a stabilized form of GHRH with a modification that prevents it from being broken down as quickly as natural GHRH. When injected, it reaches the pituitary gland and stimulates the release of growth hormone in pulses that closely mimic the natural pattern. GH then stimulates the liver to produce IGF-1, and together GH and IGF-1 shift the body away from visceral fat storage and toward fat mobilization. In HIV patients who accumulate abdominal fat as a drug side effect, restoring this GH axis activity helps reduce the excess visceral fat. The effect works through the body's own GH regulatory system rather than bypassing it.

🛡️ Research Safety Observations

FDA-approved with a well-characterized safety profile from clinical trials. Common side effects include fluid retention, joint and muscle discomfort, and peripheral edema — consistent with GH elevation. Blood glucose monitoring is recommended due to GH's effects on insulin sensitivity. It is contraindicated in people with active malignancy. Use outside the approved HIV lipodystrophy indication should be under medical supervision.

📋 Research Snapshot

High Evidence

This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.

Published Research Ranges

1–2mg/day subcutaneous in clinical trials

Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

📄 Research Sources

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Tesamorelin, a GHRH Analogue, Reduces Visceral Fat in HIV-Infected Patients (LASSO Study)

New England Journal of Medicine • 2010 • DOI: 10.1056/NEJMoa0912812

Tesamorelin

Want More Detailed Research?